Drug Control Division**IMPORTANT** No later than January 1, 2023, each pharmacy shall post a sign notifying consumers that they may visit the Department of Consumer Protection website for information concerning the safe storage of prescription drugs and the disposal of unused and expired prescription drugs. To download materials, click here.
- Connecticut Comprehensive Drug Laws (Updated June 2022)
- Refill/reissue prescriptions of Schedule II Medications
- Transfer of Drugs For Hospital Pharmacy and Licensed Pharmacy
- Dispensing of Medication from Hospitals (20-622)
- Business Resources
- Medication Shortage Resources
- Sterile Compounding Guidance Document 4-2020
- Pharmacist Role in COVID-19 testing
Commission of Pharmacy - Find meeting minutes, members and other pharmacy related information and more.
Pharmacy Complaints - Learn how to file a complaint about a pharmacy.
Preventing Prescription/Medication Errors - Find tips for protecting yourself against prescription/medication errors.
Prescription Monitoring Program - Find information about the Connecticut Prescription Monitoring and Reporting System and more.
Medical Marijuana Program - Registration, practitioners information, qualifying conditions, frequently asked questions and more.
Registrant Resources and Guidance Documents - Find documents that may be help for different disciplines regulated by the Drug Control Division.
Law Enforcement Resources - Find general information about medication, charges and more.
Statutes and Regulations - Find law information regarding the laws that pertain to the Drug Control Division.Certificate of Free Sale - Click here for the certificate of free sale documents required by the Drug Control Division.
Latest News/Quick Resource
Gabapentin and Naloxone in the CPMRS
Controlled Substance Prescribing Guidance
Return of Prescription Drugs to Pharmacies
Epinephrine in Authorized Entities
Designated Pharmacist Requirements for Sterile Pharmaceutical Preparation
Electronic Prescribing of Controlled Substances
K2 and Spice: The Danger of Synthetic Cannabinoids
- Public Act 23-19 An Act Concerning Pharmacies and Pharmacists
- Section 1: Definition Updates
- Section 2: Pharmacist COVID, Influenza and HIV testing, HIV Prophylaxis Treatment Regulations
- Section 3: Mobile Pharmacy
- Section 4: Unscheduled Pharmacy Closing Plans, Pharmacy Pick-Up Lockers
- Section 5: Pharmacist Immunization Update and Epinephrine Use
- Section 6-8: Institutional Pharmacy License
- Regulations: Drug Schedule Updates (February 10, 2023)
- Public Act 22-80 An Act Concerning Childhood Mental and Physical Health Services in Schools
- Section 7: Opioid antagonist administration by school personnel
- Section 9: Distribution of opioid antagonists to a local or regional board of education
- Public Act 22-81 An Act Expanding Preschool and Mental and Behavioral Services for Children
- Section 19: Safe storage and disposal of prescription drugs
- Section 20: Safe storage and disposal of cannabis and cannabis products
- Section 32: Telehealth extension
- Public Act 22-92 An Act Concerning Various Revisions to the Public Health Statutes
- Section 24: Administration of influenza vaccine to persons between the ages of 12 and 17
- Public Act 22-108 An Act Concerning Opioids
- Section 2: Excluding certain test types and uses from being included in Drug Paraphernalia (fentanyl test strips, etc.)
- Section 3: Transportation of controlled substances by practitioners
- Public Act 22-118: An Act Adjusting the State Budget for the Biennium Ending June 30,2023, Concerning Provisions Related to Revenue, School Construction and Other Items to Implement the State Budget and Authorizing and Adjusting Bonds of the State.
- Section 69-70: Collaborative Drug Therapy Management
- Section 71: Pharmacist License Renewal
- Regulations: Shared Pharmacy Services (Effective February 18, 2022)
- Public Act 21-9 An Act Concerning Telehealth
- Section 7: Medical Marijuana
- Public Act 21-37 An Act Concerning Department of Consumer Protection Licensing And Enforcement, Antitrust Issues and the Palliative Ue of Marijuana and Revisions to the Liquor Control Act
- Public Act 21-182 Veterinarians are exempt from reporting insulin drugs, glucagon drugs, diabetes devices and diabetic ketoacidosis devices for animal patients
- Public Act 21-192 An Act Concerning Various Pharmacy Statutes
- Section 1: Definition Updates
- Section 2: Automated Prescription Dispensing Machine
- Section 3: Syringe Services Machines
- Section 4: Collaborative Drug Therapy Management Changes
- Section 5: Outpatient Treatment Program Data in the Prescription Drug Monitoring Program
- Public Act 20-2 An Act Concerning Telehealth
- Section 2: Transfer of unfilled prescriptions for Schedule II, III, IV, and V medication
- Public Act 20-4 An Act Concerning Diabetes and High Deductible Health Plans
- Section 3: Pharmacist can prescribe insulin drugs, glucagon drugs, diabetes devices or ketoacidosis devices in certain circumstances
- Section 4: Notice to Pharmacies
- Section 5: Uploading insulin drugs, glucagon drugs, diabetes devices or ketoacidosis devices to the PDMP
- Public Act 19-191
An Act Addressing Opioid Use
- Section 1: Pharmacist Counseling
- Section 3: Pharmacy Technician Delegate in the Connecticut Prescription Monitoring and Reporting System
- Section 4: Suspicious Order Monitoring
- Section 6: Pain Agreements/Care Plan for Treatment of Pain with Opioids for Greater than 12 weeks
- Section 7: Naloxone at Institutions of Higher Education
- Public Act 19-19 An Act Concerning Epinephrine Auto Injectors (Effective From Passage)
- Public Act 19-177 An Act Making Changes to Department of Consumer Protection Enforcement Statutes
- Section 28: Sterile Compounding
- Section 29: Pharmacy to report legal action commenced by federal or state agency
- Section 30: Classification of Connecticut Controlled Substances
- Section 31: Marijuana Products Schedule Changes
- Public Act 19-98 An Act Concerning the Scope of Practice of Advanced Practice Registered Nurses
- Section 22 and 23: Advanced practice registered nurses and collaborative drug therapy management
- Public Act 19-38 An Act Concerning Increasing the Penalties for Sale of Fentanyl
- Public Act 19-13 An Act Concerning the Sale of Cigarettes, Tobacco Products, Electronic Nicotine Delivery Systems and Vapor Products to Persons Under Age Twenty-One
- Public Act 18-166 (Effective 7/1/2018)
- Section 2: Self and Family Prescribing of Controlled Substances Limitation
- Section 3: Naloxone Distribution Agreements
- Public Act 18-148 (Effective 7/1/18)
- Section 1: Telehealth - expansion to add controlled substances for a psychiatric disability or substance use disorder
- Section 2: Prevents practitioners using telehealth from receiving a waiver from electronic prescribing of controlled substances
- Public Act 18-74 (Effective 10/1/2018) - Biologic products
- Public Act 18-16 (Effective 1/1/19)
- Section 1: Penalty per violation of the chapter
- Section 2: Fees for filing changes for Non-Resident Pharmacies
- Section 3: Suspicious order reporting for Manufacturers and Wholesalers
- Section 4: Annually controlled substance inventory
- Section 5: Perpetual inventory for Schedule II medications with monthly reconciliation
- Section 6: Sterile compounding
- Public Act 17-131 An Act Preventing Prescription Opioid Diversion and Abuse
- Section 1: Data Sharing
- Section 2: Drug destruction
- Section 3: Electronic Prescribing of Controlled Substances
- Section 4: Voluntary nonopioid directive form
- Section 5: Prescribing of Opioids update
- Section 6: Medication assisted treatment
- Section 12: Naloxone standing order
- Public Act No. 16-43 An Act Concerning Opioids and Access to Overdose Reversal Drugs.
- Section 1: Naloxone prescribing, dispensing and administration update
- Section 7: Prescribing of Opioids (7 day limit)
- Section 8: Agent of the prescriber (Prescription Monitoring Program)
- Section 9: Prescription Monitoring Program (daily reporting, veterinary uploads, agent of the prescriber)
- Manufacturer APRN Expenditure Reporting
Brochure: Medication Drop-Box Program
HYDROCODONE MOVES TO SCHEDULE II
Prescriptions issued before October 6, 2014: October 6, 2014/April 8, 2015 : Any prescriptions for HCPs that are issued before October 6, 2014, and authorized for refilling, may be dispensed in accordance with 21 CFR 1306.22-1306.23, 1306.25, and 1306.27, if such dispensing occurs before April 8, 2015.
Prescriptions issued on or after October 6, 2014 : October 6: 2014 : No prescription for HCPs issued on or after October 6, 2014 shall authorize any refills.
Source: Federal Register
Authority: 21 U.S.C. 829(a); 21 CFR part 1306 and subpart C of 21 CFR part 1311.